Alliance Cancer Specialists,

Horsham, Pennsylvania 19044

2 studies enrolling now · 8 studies all time

What they study most

Breast Cancer, Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Endometrial Cancer, Esophageal Adenocarcinoma, Esophageal Cancer, Esophageal Squamous Cell Cancer, Gastric Cancer, Gastroesophageal Cancer, HER-2 Protein Overexpression, Hormone Receptor Positive HER-2 Negative Breast Cancer, KRAS Activating Mutation

Studies at this site

• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer — Recruiting now
• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors — Recruiting now
• MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles — Recruiting now
• Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study — Running, not enrolling
• A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure — Running, not enrolling
• Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors — Running, not enrolling
• Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients — Running, not enrolling
• Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 — Stopped early